Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052666/SGN-MESOC2 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

NCT06466187 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT06466187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06466187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052666/SGN-MESOC2 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
August 2, 2024
Completion date
May 27, 2026
Enrollment
19 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, colorectal neoplasms, endometrial, mesothelioma, other solid tumors, ovarian neoplasms, pancreatic adenocarcinoma